GENinCode Partners with Genesupport to Expand Access to ROCA® Test in Switzerland

December 10, 2024 06:59 PM AEDT | By Team Kalkine Media

Google News:

GENinCode Partners with Genesupport to Expand Access to ROCA® Test in Switzerland — Image source: shutterstock

Recent News

World Digital Introduces Innovative E‑Commerce Strategies Amid Global...

Alex Miller Keeps Classic Country Flame Burning With Alan Jackson Song...

Trump earns over $600 million from crypto, holds assets worth at least...

Oil in biggest gain since 2022 as Israel hits Iran, but Citi warns gai...

Highlights

GENinCode partners with Genesupport SA to expand ROCA® Test availability across Switzerland.

The ROCA Test, recommended by NICE in March 2024, is designed for women at high risk of ovarian cancer.

The collaboration will support over 11,000 women in Switzerland, focusing on those with BRCA gene mutations.

GENinCode Plc (LSE:GENI), a UK-based predictive genetics company focused on preventing cardiovascular disease and ovarian cancer risk, has announced a partnership with Genesupport SA, part of the Sonic Switzerland network of laboratories. This collaboration aims to make the ROCA® Test more widely available in Switzerland, allowing women at high risk for ovarian cancer (OC) to access advanced screening.

In March 2024, the ROCA Test received a recommendation from the National Institute for Health and Care Excellence (NICE) as the preferred method for ovarian cancer surveillance in high-risk individuals who wish to defer risk-reducing surgery. Following this milestone, Genesupport SA will offer the ROCA Test through all Sonic Switzerland diagnostic and genetic companies, including Genesupport, Medigenome Medisupport, Medica, Medisyn, and Dr. Risch. These companies cover major Swiss cities such as Geneva, Lausanne, Bern, and Zurich, along with regional centers in St. Gallen, Zug, Lucerne, and Lugano/Locarno.

The ROCA Test will be available to women who are BRCA positive and have not undergone risk-reducing surgery, supporting a population of over 11,000 women at high risk for ovarian cancer. Genesupport's network is also affiliated with key tumor centers and hospitals across Switzerland, such as Hirslanden and the Swiss Medical Network, making the test accessible to a wide demographic.

Ovarian cancer (OC) remains a leading cause of cancer-related death globally, with over 300,000 new cases reported annually. Early detection significantly improves treatment outcomes, and the ROCA Test offers a crucial tool for identifying the disease in its earlier, more treatable stages. The test uses a proprietary algorithm that calculates an individual’s OC risk, considering factors like age and CA-125 blood test results. The test has been clinically evaluated through numerous prospective studies, demonstrating its high accuracy and ability to detect ovarian cancer at earlier stages.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.